Evaluation of sFlt-1/PlGF Ratio ,OPG and sEng as Predictive Biomarkers in the Diagnosis and Treatment Evaluation of Preeclampsia

Recruiting now

Conditions studied: Preeclampsia, Gestational Hypertension, Hypertensive Disorders of Pregnancy

In brief

his study investigates the effectiveness of three specific biological markers (biomarkers) in the blood-the sFlt-1/PlGF ratio, soluble endoglin (sEng), and osteoprotegerin (OPG)-to better diagnose and monitor preeclampsia. Preeclampsia is a serious pregnancy complication characterized by high blood pressure and potential organ damage that affects 2-8% of pregnancies worldwide

Key facts

Study ID

NCT07349277

Run by

Ammar Jassim Abed

People needed

120

Starts

2025-10-10

Expected to finish

2026-04-30

Last updated by the study team

2026-01-20

Who can join

Age: 18 and older, up to 45. Sex: female. Healthy volunteers: accepted.

You may not qualify if…

• Chronic hypertension
• Renal disease
• Diabetes mellitus
• Multiple gestations
• Autoimmune disorders

Where it is running

• Bint Al Huda Maternity Hospital — Nasiriyah, Dhi Qar, Iraq (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.